Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
Introduction: The most current treatment of multiple myeloma is based on a combination of drugs, including immunomodulators and proteasome inhibitors. The bortezomib, thalidomide, and dexamethasone (VTD) and thalidomide and dexamethasone (TD) regimens are commonly used as a first-line treatment due...
Saved in:
Main Authors: | Juan M. Cano-Calderón, Juan F. Zazueta-Pozos, Adán G. Gallardo-Rodríguez, Carlos Martínez-Murillo, Irma Olarte-Carrillo, Adolfo Martínez-Tovar, Christian O. Ramos-Peñafiel |
---|---|
Format: | Article |
Language: | English |
Published: |
Permanyer
2025-01-01
|
Series: | Revista Médica del Hospital General de México |
Subjects: | |
Online Access: | https://www.hospitalgeneral.mx/frame_eng.php?id=240 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Bortezomib, thalidomide, and dexamethasone versus bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a systemic review and meta-analysis
by: Yin-Che Wang, et al.
Published: (2025-12-01) -
Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma
by: Ka-Won Kang, et al.
Published: (2025-02-01) -
Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
by: Michael Dolph, et al.
Published: (2021-08-01) -
Metabolomics approach reveals key plasma biomarkers in multiple myeloma for diagnosis, staging, and prognosis
by: Xiaoxue Wang, et al.
Published: (2025-02-01) -
Synchronous multiple myeloma and lung adenocarcinoma: A clinical series
by: Fang Ye, et al.
Published: (2024-04-01)